Markets
UBS Downgrades Apogee Therapeutics After AbbVie Deal: What Traders Need to Know
UBS has downgraded Apogee Therapeutics following its deal with AbbVie, raising questions about valuation and near-term upside. Here's what the move means for traders across all time horizons.